Nintendo va développer un appareil pour mesurer le sommeil et la fatigue.

Le créateur de jeux-vidéos japonais Nintendo va développer un appareil pour mesurer la fatigue des utilisateurs et étudier leur sommeil, a déclaré Satory Iwata le jeudi 30 octobre 2014. Il s'agit de la première offre de la toute nouvelle division de Nintendo sur la santé. L'appareil sera développé avec la compagnie américaine ResMed Inc, qui développe des produits pour traiter les problèmes de sommeil et sera disponible dans le courant de l'année fiscale se terminant mars 2016.

Amid ‘Right To Try’ Debate, myTomorrows Raises €4.5M To Give Patients Access To Development-Stage Drugs

myTomorrows, the Dutch startup that wants to disrupt the way patients with unmet medical needs access development-stage treatments — drugs that are still undergoing clinical trials and working there way through a lengthy regulatory approval process — has raised €4.5 million (~$6m) in new funding. The round is being led by by London-based tech VC Balderton Capital, and Sofinnova Partners, the Paris-based VC fund known in-part for investing in the life sciences.

With $100 Million, Entrepreneur Sees Path to Disrupt Medical Imaging.

A scanner the size of an iPhone that you could hold up to a person’s chest and see a vivid, moving, 3-D image of what’s inside is being developed by entrepreneur Jonathan Rothberg. Rothberg says he has raised $100 million to create a medical imaging device that’s nearly “as cheap as a stethoscope” and will “make doctors 100 times as effective.” The technology, which according to patent documents relies on a new kind of ultrasound chip, could eventually lead to new ways to destroy cancer cells with heat, or deliver information to brain cells. Rothberg has a knack for marrying semiconductor technology to problems in biology.

Fabrication de tissu cardiaque vascularisé à partir de cellules-souches IPS humaines.

L'équipe du professeur Jun Yamashita, du centre de recherche sur les cellules IPS à Kyoto, a mis au point une technique novatrice permettant de fabriquer des feuillets de tissu cardiaque intégré à partir de cellules-souches IPS. Les résultats sont encourageants en termes de taux de survie de ces tissus lors de transplantations sur des coeurs de souris endommagés.

1. Concept

Corporate Investment into Digital Health & Health IT Industry Hits Record Level.

According to CB Insights data, digital health and health IT companies racked up $2.2 billion in funding through the first half of 2014. And as digital health startups pulled in record funding, corporate investors from Google to Merck to BlueCross BlueShield are actively getting into the fray.

This report takes an in-depth look at corporate investments into digital health & health IT space. Specifically, it looks at financing, stage, geography trends to the space. All of the corporate investment data covered is available on the CB Insights venture capital database.

3 important lessons from HealthBeat.

HealthBeat 2014 is behind us, but I’d wager that many of us who were in attendance are still thinking about some of the central themes discussed. Several of them kept coming up in the sessions and in conversations in the hallways.

Our health system is broken; everybody knows that. Some of the discussion at HealthBeat centered on identifying the real problems, and some of it focused on new technology and tactics for fixing the problems.

Zeltia aumenta su beneficio un 24,3% gracias al tirón de Yondelis.

Zeltia ha ganado 17,5 millones de euros entre enero y septiembre de 2014, cifra que supone un incremento del 24,3% respecto al mismo periodo del ejercicio anterior, una mejora que la compañía ha atribuido a la mejora de las ventas y a "la optimización de costes".

En este sentido, la ventas del grupo han crecido un 7%, hasta 116,9 millones, gracias al tirón de su compuesto antitumoral estrella, Yondelis, que ha aportado 57,4 millones, un 8% más, y a la mejora, también del 8%, en la facturación de su negocio de química de gran consumo, hasta los 55,1 millones.

I Congreso Nacional de Wearables y Big Data en Salud

 COM SALUD organiza, el próximo 18 de noviembre de 2014, el I Congreso Nacional de Wearables y Big Data en Salud con el objetivo de congregar en un mismo espacio a profesionales de los ámbitos sanitario y tecnológico y debatir sobre la posible evolución y expansión de los Wearables y el Big Data aplicados a la salud. El evento, que tendrá lugar en las instalaciones de la Escuela Universitaria de Diseño e Innovación (ESNE) en Madrid (Avenida de Alfonso XIII, 97) arrancará a las diez de la mañana con un amplio catálogo temático entre los que destacan la integración de wearables y Big Data, el nuevo papel de los profesionales de la salud y los pacientes, las consideraciones étic
Nov 18 2014, 9:00am CET

Bright.md raises $1M for remote primary care platform.

The investment money continues to roll into the virtual and mobile care space. In the U.S. we now spend about $150 billion a year to treat simple primary care health problems, and many of those problems don’t require the hands-on attention of a physician.

Many of the telemedicine startups we’ve seen sell their service directly to consumers, but Portland, Oregon-based Bright.md offers a technology platform that medical groups can use to care for some types of patients remotely.

Páginas

Suscribirse a RSS - salud